Hodgkin's lymphoma (Cancer)
Information
- Disease name
- Hodgkin's lymphoma
- Disease ID
- DOID:8567
- Description
- "A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell." [url:https\://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma, url:https\://www.ncbi.nlm.nih.gov/pubmed/22835602]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01483664 | Active, not recruiting | Communication Skills Intervention to Promote Transition Into Survivorship | November 2011 | November 2024 | |
| NCT04875195 | Active, not recruiting | Phase 2 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | June 7, 2021 | December 31, 2025 |
| NCT02576496 | Active, not recruiting | Phase 1 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | March 2016 | December 2023 |
| NCT03615664 | Active, not recruiting | Phase 2 | The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD | November 6, 2017 | September 30, 2024 |
| NCT01192464 | Active, not recruiting | Phase 1 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma | May 10, 2011 | October 2033 |
| NCT00285259 | Completed | Phase 2 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | January 31, 2006 | November 30, 2010 |
| NCT00333190 | Completed | N/A | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | September 2005 | March 2009 |
| NCT00352027 | Completed | Phase 2 | Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | July 20, 2006 | November 15, 2022 |
| NCT00359892 | Completed | Phase 2 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma | July 2006 | November 2008 |
| NCT00388349 | Completed | Phase 2 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | September 2001 | September 2010 |
| NCT00428688 | Completed | Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma | July 2009 | August 2014 | |
| NCT00481871 | Completed | Phase 1/Phase 2 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | May 2007 | August 2011 |
| NCT00510315 | Completed | Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant | July 2007 | January 2016 | |
| NCT00520130 | Completed | Phase 1/Phase 2 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | October 30, 2007 | December 31, 2018 |
| NCT00533923 | Completed | Phase 2 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | December 2002 | January 2007 |
| NCT00670592 | Completed | Phase 1/Phase 2 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | March 2008 | February 2013 |
| NCT00741871 | Completed | Phase 1 | A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | July 2008 | October 2011 |
| NCT00784537 | Completed | Phase 2/Phase 3 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients | September 2008 | January 2016 |
| NCT00791011 | Completed | Phase 1 | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | February 2008 | August 2011 |
| NCT00061672 | Completed | Phase 2 | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | April 2003 | |
| NCT00792467 | Completed | Phase 1/Phase 2 | Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma | February 2008 | September 2010 |
| NCT00066092 | Completed | Phase 2 | Pegfilgrastim PBPC Mobilization Study | April 2003 | October 2004 |
| NCT00143559 | Completed | Phase 2 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | August 2005 | January 2009 |
| NCT00273936 | Completed | Phase 1 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | January 2006 | |
| NCT00283439 | Completed | Phase 1/Phase 2 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | October 2005 | September 2008 |
| NCT00887718 | Completed | N/A | Positron Emission Tomography(PET) in Lymphoma Assessment | August 2007 | June 2011 |
| NCT00896454 | Completed | Phase 2 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | November 16, 2009 | August 21, 2013 |
| NCT01034163 | Completed | Phase 3 | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) | June 2010 | May 2012 |
| NCT01037478 | Completed | Phase 2 | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma | December 2009 | March 2013 |
| NCT01164345 | Completed | Phase 2 | Mozobil for Autologous Stem Cell Mobilization | June 2010 | May 2015 |
| NCT01169636 | Completed | Phase 1/Phase 2 | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | January 31, 2011 | May 17, 2017 |
| NCT01180010 | Completed | Low Dose Chest Computed Tomography (CT) Screening | August 2010 | September 2015 | |
| NCT01181271 | Completed | Phase 2 | Tandem Auto-Allo Transplant for Lymphoma | August 2010 | February 2016 |
| NCT01203020 | Completed | Phase 2 | Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation | October 12, 2010 | September 27, 2021 |
| NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
| NCT01304849 | Completed | N/A | Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes | January 2011 | September 2013 |
| NCT01342289 | Completed | Phase 1 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | August 2011 | March 2018 |
| NCT01358747 | Completed | Phase 3 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL | May 2011 | |
| NCT01364363 | Completed | N/A | Unrelated Donor Stem Cell Transplantation | March 2005 | July 2015 |
| NCT01402687 | Completed | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) | October 2010 | June 2013 | |
| NCT01408563 | Completed | Phase 2 | Reduced Intensity Double Umbilical Cord Blood Transplantation | December 2011 | June 2017 |
| NCT01478191 | Completed | Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT | May 2010 | June 2011 | |
| NCT01508312 | Completed | Phase 2 | Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma | January 5, 2012 | March 14, 2024 |
| NCT01597219 | Completed | Phase 2 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers | March 2013 | January 2024 |
| NCT01767766 | Completed | Phase 1 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | January 7, 2013 | February 2018 |
| NCT01877005 | Completed | Phase 2 | A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | July 4, 2013 | June 12, 2018 |
| NCT02003625 | Completed | Phase 2 | Meloxicam vs Placebo for Mobilization | October 2013 | April 2019 |
| NCT02059239 | Completed | Phase 1/Phase 2 | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | June 4, 2014 | June 15, 2020 |
| NCT02164006 | Completed | Phase 1 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | June 11, 2014 | May 2016 |
| NCT02208037 | Completed | Phase 2 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | August 2014 | October 2017 |
| NCT02223052 | Completed | Phase 1 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | October 27, 2014 | December 18, 2018 |
| NCT02404818 | Completed | Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy | April 2015 | April 14, 2021 | |
| NCT02581007 | Completed | Phase 2 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | October 26, 2015 | December 28, 2020 |
| NCT02593123 | Completed | Phase 2 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | November 4, 2015 | March 18, 2022 |
| NCT02613598 | Completed | Phase 1 | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | May 12, 2016 | June 7, 2021 |
| NCT02719821 | Completed | N/A | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation | March 2016 | June 2, 2017 |
| NCT03343652 | Completed | Phase 1/Phase 2 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma | May 27, 2017 | March 27, 2020 |
| NCT03722147 | Completed | Phase 1/Phase 2 | A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma | August 13, 2018 | December 31, 2021 |
| NCT04005703 | Completed | Whole-body MRI in Pediatric Hodgkin's Lymphoma | June 2011 | September 2020 | |
| NCT04028804 | Completed | FLT PET: A Pilot Study in Lymphoma Patients | July 2011 | December 2014 | |
| NCT02917083 | Recruiting | Phase 1 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) | May 8, 2017 | February 2040 |
| NCT02356159 | Recruiting | Phase 1/Phase 2 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | September 24, 2015 | December 1, 2024 |
| NCT01788839 | Recruiting | Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | February 2013 | February 2025 | |
| NCT05355051 | Recruiting | Phase 2 | A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | October 5, 2022 | December 31, 2026 |
| NCT04665063 | Recruiting | N/A | A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma | October 22, 2020 | October 21, 2025 |
| NCT03198234 | Recruiting | Phase 1 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders | August 30, 2017 | July 2025 |
| NCT02259556 | Recruiting | Phase 1/Phase 2 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas | October 2014 | October 2029 |
| NCT05337735 | Suspended | Phase 2 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | August 5, 2022 | April 1, 2025 |
| NCT00963495 | Terminated | Phase 1 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | August 2009 | September 2013 |
| NCT00984165 | Terminated | Phase 2 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | January 19, 2010 | January 31, 2013 |
| NCT01032148 | Terminated | Phase 1 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | December 2009 | January 2017 |
| NCT01929941 | Terminated | Phase 1 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | September 2013 | August 2014 |
| NCT01643603 | Terminated | Phase 1 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | May 2012 | October 9, 2018 |
| NCT01699581 | Terminated | Phase 2 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | September 2012 | October 2015 |
| NCT01742793 | Terminated | Phase 1 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) | October 2012 | August 2016 |
| NCT01745913 | Terminated | Phase 2 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | October 26, 2012 | April 29, 2015 |
| NCT00838955 | Terminated | Phase 2 | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | January 2009 | October 2017 |
| NCT00866333 | Terminated | Phase 2 | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma | April 13, 2009 | February 8, 2013 |
| NCT00879528 | Terminated | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory | May 2009 | September 2015 | |
| NCT00901303 | Terminated | N/A | Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma | October 2008 | May 23, 2011 |
| NCT00626626 | Terminated | Phase 1/Phase 2 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | May 2007 | January 2010 |
| NCT01350258 | Terminated | Phase 1/Phase 2 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | April 2011 | August 2012 |
| NCT00358982 | Terminated | Phase 2 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | August 2006 | January 2009 |
| NCT00496431 | Terminated | Phase 1/Phase 2 | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients | May 2007 | March 2009 |
| NCT00276159 | Terminated | Phase 2 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | January 2006 | November 2008 |
| NCT01532635 | Terminated | Phase 2 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | March 2012 | May 2013 |
| NCT03776864 | Terminated | Phase 2 | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | September 26, 2019 | September 14, 2021 |
| NCT01609816 | Terminated | Phase 1 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | February 12, 2015 | October 9, 2018 |
| NCT03474133 | Unknown status | Phase 2 | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) | May 14, 2019 | December 2, 2023 |
| NCT00816959 | Unknown status | Phase 3 | Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | July 2011 | April 2014 |
| NCT01884441 | Unknown status | Phase 2 | Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | July 2011 | July 2016 |
| NCT01300156 | Unknown status | Phase 2 | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) | February 2011 | December 2013 |
| NCT01884428 | Unknown status | Phase 1 | Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | July 2011 | December 2015 |
| NCT01399931 | Unknown status | Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions | January 2012 | January 2017 | |
| NCT02722733 | Unknown status | Phase 3 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | March 2016 | April 2017 |
| NCT00441818 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma | May 2006 | June 2007 |
| NCT01983761 | Unknown status | Phase 1/Phase 2 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | November 2013 | |
| NCT01704742 | Withdrawn | Prospective Study of Lymphoproliferative Diseases | |||
| NCT02408042 | Withdrawn | Phase 1/Phase 2 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | April 2015 | November 2015 |
| NCT01316146 | Withdrawn | Phase 1 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | October 3, 2011 | May 4, 2022 |
- Disase is a (Disease Ontology)
- DOID:0060058
- Cross Reference ID (Disease Ontology)
- EFO:0000183
- Cross Reference ID (Disease Ontology)
- GARD:2714
- Cross Reference ID (Disease Ontology)
- ICD10CM:C81
- Cross Reference ID (Disease Ontology)
- ICD9CM:201
- Cross Reference ID (Disease Ontology)
- MESH:D006689
- Cross Reference ID (Disease Ontology)
- MIM:236000
- Cross Reference ID (Disease Ontology)
- MIM:300221
- Cross Reference ID (Disease Ontology)
- MIM:400021
- Cross Reference ID (Disease Ontology)
- NCI:C9357
- Cross Reference ID (Disease Ontology)
- ORDO:98293
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:118599009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0019829
- Exact Synonym (Disease Ontology)
- HL
- Exact Synonym (Disease Ontology)
- Hodgkin disease
- Exact Synonym (Disease Ontology)
- Hodgkin lymphoma
- Exact Synonym (Disease Ontology)
- Hodgkin's sarcoma
- Exact Synonym (Disease Ontology)
- Hodgkins lymphoma
- Exact Synonym (Disease Ontology)
- stage I Subdiaphragmatic Hodgkin Lymphoma
- Exact Synonym (Disease Ontology)
- stage II Subdiaphragmatic Hodgkin Lymphoma